Ortho evra, Evra(norelgestromin)
Ethinyl Estradiol / Norelgestromin, Evra, Onsura, Xulane (norelgestromin) is a small molecule pharmaceutical. Norelgestromin was first approved as Ortho evra on 2001-11-20. It is used to treat amenorrhea and uterine hemorrhage in the USA. It has been approved in Europe to treat contraception.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Combinations
Ethinyl estradiol norelgestromin, Onsura, Xulane (discontinued: Ortho evra)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ethinyl estradiol
+
Norelgestromin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ORTHO EVRA | Johnson & Johnson | N-021180 DISCN | 2001-11-20 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| norelgestromin and ethinly estradiol | ANDA | 2022-03-30 |
| norelgestromin and ethinyl estradiol | ANDA | 2024-11-27 |
| xulane | ANDA | 2024-02-27 |
| zafemy | ANDA | 2024-01-05 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | — | — | 5 | 2 | 6 | 4 | 7 | 24 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | 1 | — | 4 |
| Fatty liver | D005234 | EFO_0003934 | — | — | — | 1 | 1 | — | 2 |
| Menopause | D008593 | EFO_0003922 | N95 | — | — | — | 2 | — | 2 |
| Left ventricular dysfunction | D018487 | — | — | — | — | — | 1 | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | 1 | — | 1 |
| Ventricular dysfunction | D018754 | — | — | — | — | — | 1 | — | 1 |
| Tissue adhesions | D000267 | — | — | — | — | — | 1 | — | 1 |
| Bone diseases | D001847 | — | M89.9 | — | — | — | 1 | — | 1 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | 1 | — | — | 2 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | 1 | — | — | 1 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | — | — | 1 | — | — | 1 |
| Premature menopause | D008594 | — | E28.31 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception behavior | D003268 | — | — | 1 | 1 | — | — | 1 | 3 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | 1 | — | — | — | 2 |
| Thrombosis | D013927 | — | — | — | 1 | — | — | 1 | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | 1 | 2 |
| Metrorrhagia | D008796 | — | N92.1 | — | 2 | — | — | — | 2 |
| Menstruation disturbances | D008599 | — | N91.5 | — | 1 | — | — | 1 | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | — | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | — | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 2 | — | — | — | — | 2 |
| Pregnancy rate | D018873 | — | — | 1 | — | — | — | — | 1 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 1 | — | — | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | — | — | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | — | — | — | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | — | — | — | — | 1 |
| Dementia | D003704 | EFO_0003862 | F03 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | — | — | — | 3 | 3 |
| Thromboembolism | D013923 | — | — | — | — | — | — | 3 | 3 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 2 | 2 |
| Infarction | D007238 | EFO_0009463 | — | — | — | — | — | 2 | 2 |
| Venous thrombosis | D020246 | — | I82.40 | — | — | — | — | 1 | 1 |
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 1 | 1 |
| Breast density | D000071060 | — | — | — | — | — | — | 1 | 1 |
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 1 | 1 |
| Dysmenorrhea | D004412 | — | N94.6 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Norelgestromin |
| INN | norelgestromin |
| Description | Norelgestromin, or norelgestromine, sold under the brand names Evra and Ortho Evra among others, is a progestin medication which is used as a method of birth control for women. The medication is available in combination with an estrogen and is not available alone. It is used as a patch that is applied to the skin.
|
| Classification | Small molecule |
| Drug class | estrogens; progestins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC |
Identifiers
| PDB | — |
| CAS-ID | 53016-31-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200807 |
| ChEBI ID | — |
| PubChem CID | 62930 |
| DrugBank | DB06713 |
| UNII ID | R0TAY3X631 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Norelgestromin
+
Ethinyl estradiol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 567 documents
View more details
Safety
Black-box Warning
Black-box warning for: Norelgestromin and ethinly estradiol, Norelgestromin and ethinyl estradiol, Xulane, Zafemy
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
23,485 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use